Compound 1 mIDH-1 Inhibitor CNS Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers harboring mutant IDH-1 cells face challenges in achieving sufficient brain drug exposure, sustaining steady-state drug plasma concentrations, and selectively inhibiting 2-HG production across various R132 mutations while avoiding wild-type IDH-1 and IDH-2 cells.
Innovation Solution
The development of Compound 1, a small molecule inhibitor that selectively targets and inhibits mutant IDH-1 cells with R132 mutations, achieving desirable CNS penetration and maintaining therapeutic plasma concentrations through optimized dosing regimens, including a total daily dose of 300 mg administered as 150 mg twice daily, to effectively treat cancers like AML and glioma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current mIDH-1 inhibitors are used to treat cancers with R132 mutations, then 2-HG production is inhibited, but sufficient brain drug exposure is not achieved
Solution Approach 1:
The patent modifies the chemical structure of mIDH-1 inhibitors by introducing specific structural modifications at key positions to enhance blood-brain barrier penetration. These parameter changes in molecular structure enable the compound to achieve both effective 2-HG inhibition and sufficient brain exposure simultaneously
Solution Approach 2:
The invention creates a composite pharmacological profile by combining molecules with specific structural features that provide both potent mIDH-1 inhibition and CNS penetration capabilities, achieving a dual-function inhibitor that addresses both requirements
2Reliability
If dosing regimens are optimized to achieve steady-state plasma concentrations, then therapeutic efficacy is improved, but dosing complexity increases
Solution Approach 1:
The patent establishes a periodic dosing schedule of 150 mg twice daily that maintains steady-state plasma concentrations. This periodic administration pattern ensures consistent therapeutic levels while providing a clear, manageable dosing rhythm for patients
3Reliability
If selective inhibition of mutant IDH-1 is achieved, then cancer-specific efficacy is improved, but off-target effects on wild-type IDH-1 and IDH-2 increase
Solution Approach 1:
The patent achieves local quality differentiation by designing a molecule that specifically recognizes and binds to the mutant IDH-1 R132 structure with high affinity, while showing reduced affinity for wild-type IDH-1 and IDH-2. This localized selectivity ensures cancer-specific efficacy with minimal off-target effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Compound 1 demonstrates durable steady-state drug plasma concentrations, achieving >90% inhibition of 2-HG production in mutant IDH-1 cells with minimal toxic side effects, effectively treating cancers with R132 mutations across multiple forms of cancer, including those in the central nervous system.
Implementation Method 1
Compound 1 is a small molecule inhibitor of mutant forms of isocitrate dehydrogenase 1 (IDH-1) enzyme... Compound 1 selectively inhibits the production of 2-HG in mIDH-1 cancer cells
Data Source
AI summary
Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.